DANIEL JANNEY - 27 Feb 2026 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Director
Signature
/s/ Krish Krishnan, as attorney-in-fact for Daniel Janney
Issuer symbol
KRYS
Transactions as of
27 Feb 2026
Net transactions value
-$3,252,824
Form type
4
Filing time
03 Mar 2026, 18:28:41 UTC
Previous filing
26 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
JANNEY DANIEL Director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH /s/ Krish Krishnan, as attorney-in-fact for Daniel Janney 03 Mar 2026 0001198325

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale $2,597,481 -9,430 -11% $275.45 75,666 27 Feb 2026 Directly beneficially owned by Alta Bioequities, L.P. F1, F2, F3
transaction KRYS Common Stock Sale $655,343 -2,373 -3.1% $276.17 73,293 27 Feb 2026 Directly beneficially owned by Alta Bioequities, L.P. F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
F2 The transaction was executed in multiple trades ranging from $275 to $275.986. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F4 The transaction was executed in multiple trades ranging from $276 to $276.4924. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.